At a press conference at ASCO 2014, Dr Venook presents the results from a large federally funded phase III study which demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cancer and no KRAS mutations.
Read the article for more.